| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/09/2006 | US20060030545 Anti-proliferative compounds, compositions, and methods of use thereof |
| 02/09/2006 | US20060030544 enzyme inhibitors comprising 5-fluoroindole-2-carboxamide compounds, used for the treatment cancer, psoriasis, artherosclerosis, non-insulin depepndent diabetes, obesity and as immunomodulators |
| 02/09/2006 | US20060030543 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| 02/09/2006 | US20060030542 Protecting a muscarinic acetylcholine receptor in patient, by administering at least one pyrophosphates with active drug; prevent tissue damage, increasing the efficacy of a therapeutic agent |
| 02/09/2006 | US20060030539 Administering a mixture of a first compound that inhibits the polymerization of actin microfilaments or depolymerizes actin microfilaments and an anti-DNA compound; cystic fibrosis; Legionnaire's Disease; medical device-related infections, implant infections |
| 02/09/2006 | US20060030537 Ceramide kinase and uses thereof |
| 02/09/2006 | US20060030536 Combination therapies for cancer and proliferative angiopathies |
| 02/09/2006 | US20060030534 Alzheimer's, Parkinson's, multiple sclerosis, schizophrenia, epilepsy, depression and pain |
| 02/09/2006 | US20060030528 Compositions and methods for treating peripheral vascular disease |
| 02/09/2006 | US20060030526 Stable suspension formulations of erythropoietin receptor agonists |
| 02/09/2006 | US20060030525 Apolipoprotein A-I derivatives with altered immunogenicity |
| 02/09/2006 | US20060030519 Composition for reducing blood lipids |
| 02/09/2006 | US20060030045 Antisense modulation of c/ebp beta expression |
| 02/09/2006 | US20060029989 Targeting cells having Mad2 mutation for treatment and/or prevention of disease |
| 02/09/2006 | US20060029986 Prevention and treatment of cardiovascular pathologies |
| 02/09/2006 | US20060029951 Screening for serotonergic neurotransmission dysregulation disorder; detecting the presence or absence of an Tph2 mutation |
| 02/09/2006 | US20060029689 Skin protection composition |
| 02/09/2006 | US20060029688 Antiseptic composition |
| 02/09/2006 | US20060029687 comprises a carrier essentially formed of water, ethoxydiglycol and propylene glycol; anti-oxidant; high stirring speed provides for micronizaton of the components, which is responsible for the stability of the solutions |
| 02/09/2006 | US20060029686 Administering rosehips, resveratrol, astaxanthin, blackberry, blueberry, elderberry, and/or Aframomum melegueta extractto inhibit interleukin synthesis; antiinflammatory agents; cardiovascular disorders, pain, stiffness |
| 02/09/2006 | US20060029684 Synergistic treatment of DNA viral infections |
| 02/09/2006 | US20060029682 Treatment of wounds and compositions employed |
| 02/09/2006 | US20060029681 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 02/09/2006 | US20060029677 Azithromycin dosage forms with reduced side effects |
| 02/09/2006 | US20060029674 Stable amorphous Cefdinir |
| 02/09/2006 | US20060029673 A device for delivering fesoterodine (fumarate) through the skin in a dosage ofo.r-20 mg per day and is provided in a polymer matrix for uniform release;contact adhesives; sel-adhesives; impermeable backing; flatness; geratrics;drug delivery; side effect reduction |
| 02/09/2006 | US20060029670 Pharmaceutical Formulations and Method for Making |
| 02/09/2006 | US20060029669 Controlled release nateglimide formulation; reducing blood glucose concentration |
| 02/09/2006 | US20060029668 Sustained release L-arginine formulations and methods of manufacture and use |
| 02/09/2006 | US20060029663 Solid formulation |
| 02/09/2006 | US20060029662 administering N-ethyl-N'-(3-dimethylaminopropyl) urea; N-ethyl-N'-(3-dimethylaminopropyl) urea methiodide to treat arthritis; antiinflammatory agent |
| 02/09/2006 | US20060029661 Orally administrable pharmaceutical formulation |
| 02/09/2006 | US20060029658 Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs |
| 02/09/2006 | US20060029654 Analgesic patch for sports injury rehabilitation medicine and method to alleviate pain |
| 02/09/2006 | US20060029649 Stabilized antimicrobial agents |
| 02/09/2006 | US20060029647 Composition and method for use in cartilage affecting conditions |
| 02/09/2006 | US20060029643 glycosylated ceramide and a diacylglycerol in which the constituent fatty acid has an acyl group containing 8 to 18 carbon atoms; enhancing the barrier function of skin and increasing water holding capacity of the skin |
| 02/09/2006 | US20060029642 Methods and compositions for improved chromium complexes |
| 02/09/2006 | US20060029636 comprising a substrate and an active agent associated with substrate, wherein active agent suppresses production and/or activity of a TLH enzyme in collagen-producing cells and comprises a siRNA molecule or a DNA that encodes a siRNA molecule, wherein siRNA molecule inhibits translation of a TLH enzyme |
| 02/09/2006 | US20060029623 Invert emulsions comprising at least one active agent sensitive to water and cosmetic/dermatological applications thereof |
| 02/09/2006 | US20060029622 Water in oil emulsion comprising sterolesters |
| 02/09/2006 | US20060029621 Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
| 02/09/2006 | US20060029611 Prevention and treatment of amyloidogenic disease |
| 02/09/2006 | US20060029606 Insulin-like growth factor (IGF); peptide of given sequence; administered with co-agent such as doxorubicin, paclitaxel, methotrexate, tamoxifen, cyclophosphamide, vincristine, etoposide, 5-fluorouracil; anticarcinogen |
| 02/09/2006 | US20060029605 Use of ErbB receptor ligands in treating diabetes |
| 02/09/2006 | US20060029596 Administering to the tumor an adenovirus vector, overexpresses an adenovirus death protein; promoting the death of neoplastic cells; telomerase resistance; anticancer biodrugs |
| 02/09/2006 | US20060029587 For patients undergoing or who have undergone a surgical a daily nutritional supplement comprising coenzyme Q10; L-cystine; L-glutamine; L-lysine; Vitamin C; Vitamin A; about 100 Vitamin D; Vitamin B1; Vitamin B2; Vitamin B5; Vitamin B6; folic acid; calcium, selenium and zinc |
| 02/09/2006 | US20060029585 Methods for reducing morbidity |
| 02/09/2006 | US20060029582 Methods of treating neoplasia with combinations of target cell-specific adenovirus and chemotherapy |
| 02/09/2006 | US20060029578 Composition and method for the repair and regeneration of cartilage and other tissues |
| 02/09/2006 | US20060029571 Hyaluronan is combined with a polyglycol, such as polyethylene glycol; preparations may maintain their viscosity and lubricity for extended time periods (e.g., 2 years) without requiring refrigeration or special storage conditions |
| 02/09/2006 | US20060029570 Therapeutic PEG solution concentrate |
| 02/09/2006 | US20060029569 Water-in-oil emulsions with anionic groups, compositions, and methods |
| 02/09/2006 | US20060029568 Anionic polymers as toxin binders and antibacterial agents |
| 02/09/2006 | US20060029556 Aqueous-alcoholic depigmenting gels |
| 02/09/2006 | US20060029555 Caffeine, theophylline, theobromine and free radical scavenger; topically applied to the skin of an individual with heightened sensitivity to the sun |
| 02/09/2006 | US20060029552 Carrier particles for use in dry powder inhalers |
| 02/09/2006 | US20060029551 Stable particle formulations of erythropoietin receptor agonists |
| 02/09/2006 | US20060029548 Methods of diagnosing, monitoring and treating pulmonary diseases |
| 02/09/2006 | US20060029543 Treatment of B-cell lymphoma |
| 02/09/2006 | US20060026775 Administering N-Phenyl-2({[(1Z)-1-(thien-2-yl)-ethylidene]amino}oxy)acetamide for inducing and/or stimulating the growth of keratinous fibers and/or slowing the loss and/or increasing the density thereof, notably human hair and/or eyelashes |
| 02/09/2006 | DE69717294C5 Chinazolin derivate und diese enthaltende pharmazeutische zusammenstellungen Quinazoline derivatives and those containing pharmaceutical assortments |
| 02/09/2006 | DE10258007B4 Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel Aromatic Fluorglycosidderivate, pharmaceutical compositions containing them and methods for making these drugs |
| 02/09/2006 | DE102004063910A1 Verwendung von trisubstituierten Benzopyranonen Use of trisubstituted Benzopyranonen |
| 02/09/2006 | DE102004034697A1 Mit Diphenylamin oder Diphenylaminderivaten substituierte Salicylthiazole, Verfahren zu deren Herstellung und deren Verwendung With diphenylamine or diphenylamine derivatives substituted Salicylthiazole, processes for their preparation and their use |
| 02/09/2006 | DE102004034613A1 Use of condensation products produced by reacting aromatic compound with sulfonating agent and carbonyl compound followed by molecular size-dependent separation as medicaments useful for treating e.g. herpes simplex infections |
| 02/09/2006 | DE102004034043A1 Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält A solid pharmaceutical composition contains, the mirtazapine |
| 02/09/2006 | DE102004032322A1 Propellant-containing aerosol suspension useful for treating diseases e.g. asthma, pain contains active substance with chemically bound water, propellant gas or its mixture |
| 02/09/2006 | DE102004031999A1 Topical compositions with hyaluronate lyase inhibitory activity, e.g. useful as skin care and cleansing products, comprises carboxy-functional lanostanoids |
| 02/09/2006 | DE102004031588A1 Verwendung von Äpfelsäureglucosiden als Geschmacksstoffe Use of Äpfelsäureglucosiden as flavoring agents |
| 02/09/2006 | DE102004031538A1 Presentation form (obtainable by dissolving indibulin in or with a highly concentrated organic acid), useful to orally administer poorly soluble active compound indibulin, comprises a poorly soluble active compound indibulin |
| 02/09/2006 | DE102004031210A1 MLV-Kosmetikum MLV cosmetic |
| 02/09/2006 | CA2784585A1 Glycogen or polysaccharide storage disease treatment method |
| 02/09/2006 | CA2784420A1 Glycogen or polysaccharide storage disease treatment method |
| 02/09/2006 | CA2638747A1 Combination drug therapy for reducing scar tissue formation |
| 02/09/2006 | CA2612149A1 Mixture of catechins or rather polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy(bph) |
| 02/09/2006 | CA2580235A1 Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors |
| 02/09/2006 | CA2578261A1 Pyrazole derivative |
| 02/09/2006 | CA2576826A1 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| 02/09/2006 | CA2576112A1 Piperidine derivatives as histamine h3 receptor ligands |
| 02/09/2006 | CA2576109A1 Novel piperidine derivatives as histamine h3 receptor ligands for treatment of depression |
| 02/09/2006 | CA2576107A1 Medicaments for treating chronic respiratory disease |
| 02/09/2006 | CA2576102A1 Therapy device and related accessories, compositions, and treatment methods |
| 02/09/2006 | CA2576093A1 Pharmaceutical compostion containing meltrin antagonist |
| 02/09/2006 | CA2576087A1 Polymeric adhesive matrix with salified carboxylic groups for transdermal use |
| 02/09/2006 | CA2576073A1 Novel piperidine derivative for the treatment of depression |
| 02/09/2006 | CA2576028A1 Heterocyclic compounds useful as dpp- iv inhibitors |
| 02/09/2006 | CA2576022A1 Composition for accelerating calcium absorption |
| 02/09/2006 | CA2575936A1 Quinoline derivatives as neurokinin receptor antagonists |
| 02/09/2006 | CA2575933A1 Stabilised prostaglandin composition |
| 02/09/2006 | CA2575928A1 Compounds for inhibiting copper-containing amine oxidases and uses thereof |
| 02/09/2006 | CA2575906A1 Compositions forming non-lamellar dispersions |
| 02/09/2006 | CA2575894A1 Dual nk1/nk3 antagonists against schizophrenia |
| 02/09/2006 | CA2575882A1 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| 02/09/2006 | CA2575697A1 Quinoline derivatives as neurokinin receptor antagonists |
| 02/09/2006 | CA2575587A1 Carrier for enteral administration |
| 02/09/2006 | CA2575555A1 A gastric retained dosage form of gabapentin |
| 02/09/2006 | CA2575520A1 Prodrugs activated by rna-dependent dna-polymerases |
| 02/09/2006 | CA2575345A1 5-substituted 1h-pyrrolo[3,2-b]pyridines |
| 02/09/2006 | CA2575340A1 Macrocyclic beta-secretase inhibitors |